Primo Biotechnology and Antelope Surgical Solutions are collaborating on a Phase I/II clinical trial of AS1986NS, a fluorescent imaging agent, to improve the accuracy of prostate biopsies. The FDA-approved trial marks a significant step in advancing radioligand theranostics (RLT) for cancer diagnostics and therapeutics.
The study will assess the safety and efficacy of AS1986NS in prostate cancer biopsy procedures. AS1986NS enables real-time visualization of cancerous tissue, potentially enhancing diagnostic precision and reducing unnecessary procedures.
Supporting Quotes
"Partnering with Antelope Surgical Solutions aligns perfectly with Primo's mission to advance precision medicine," stated Ya-Ting Huang, PhD, Director of Research and Development at Primo Biotechnology. "We are thrilled to contribute our expertise to a trial that aims to improve cancer diagnostics and patient outcomes."
Amy Wu, MD, FACS, CEO of Antelope Surgical Solutions, added, "This collaboration is a crucial milestone in validating AS1986NS's potential to transform cancer diagnostics. Primo Biotechnology's expertise in radioligand theranostics and clinical trial management makes them an ideal partner for this groundbreaking study."
Further Applications of AS1986NS
Beyond fluorescence-guided biopsy imaging, AS1986NS will be applied to intraoperative cancer margin detection in fluorescence-guided robotic radical prostatectomy. Primo and Antelope Surgical Solutions plan to expand AS1986NS utility in upcoming FDA submissions, including radioligand therapeutic and PET imaging capabilities, to further advance precision oncology.
